ALLO
Allogene Therapeutics, Inc.
Price Chart
Latest Quote
$1.88
-0.16 (-7.84%)
Current Price
| Previous Close | $2.04 |
| Open | $2.01 |
| Day High | $2.02 |
| Day Low | $1.87 |
| Volume | 7,928,090 |
Stock Information
| Shares Outstanding | 345.15M |
| Total Debt | $81.05M |
| Cash Equivalents | $266.89M |
| Net Income | $-173.76M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $648.89M |
| EPS (TTM) | $-0.77 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $463.06M |
| Income | $-173.76M |
| Book/sh | $1.14 |
| Cash/sh | $0.77 |
| Employees | 150 |
Financial Ratios
| Quick Ratio | 9.47 |
| Current Ratio | 9.65 |
| Debt/Eq | 29.06 |
Returns & Margins
| ROA | -25.97% |
| ROE | -52.32% |
Ownership
| Insider Ownership | 11.05% |
| Institutional Ownership | 53.32% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.44 |
| P/B | 1.65 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $8.35 |
Technical Indicators
| SMA20 | $2.10 |
| SMA50 | $2.28 |
| SMA200 | $1.72 |
| RSI | 43.48 |
| ATR | 0.1343 |
| Shares Float | 269.64M |
| Short Float | 13.56% |
| Short Ratio | 3.78 |
| Volatility | 0.46 |
| Rel Volume | 1.12 |
Performance History
| Week | -13.36% |
| Month | -18.61% |
| Quarter | -18.26% |
| 6 Months | +23.68% |
| YTD | +39.26% |
| Year | +45.74% |
| 3 Years | -64.19% |
| 5 Years | -92.68% |
| 10 Years | -92.48% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $1.88 | 7,985,500 |
| 2026-06-04 | $2.04 | 7,340,800 |
| 2026-06-03 | $2.00 | 9,058,900 |
| 2026-06-02 | $2.05 | 7,373,800 |
| 2026-06-01 | $2.15 | 8,548,500 |
| 2026-05-29 | $2.17 | 10,287,600 |
| 2026-05-28 | $2.25 | 6,512,700 |
| 2026-05-27 | $2.25 | 10,685,700 |
| 2026-05-26 | $2.12 | 4,768,700 |
| 2026-05-22 | $2.00 | 4,123,500 |
| 2026-05-21 | $1.96 | 4,333,900 |
| 2026-05-20 | $1.90 | 5,201,400 |
| 2026-05-19 | $1.89 | 7,155,300 |
| 2026-05-18 | $1.94 | 6,373,800 |
| 2026-05-15 | $2.00 | 7,668,900 |
| 2026-05-14 | $2.14 | 9,164,500 |
| 2026-05-13 | $2.33 | 6,459,200 |
| 2026-05-12 | $2.30 | 10,034,100 |
| 2026-05-11 | $2.28 | 4,503,800 |
| 2026-05-08 | $2.28 | 4,476,500 |
| 2026-05-07 | $2.27 | 5,680,700 |
| 2026-05-06 | $2.31 | 7,353,000 |
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
đ° Latest News
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
Zacks âĸ 2026-05-14T14:17:00Z
Big Pharmaâs 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
24/7 Wall St. âĸ 2026-05-14T13:20:55Z
Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and ...
GuruFocus.com âĸ 2026-05-14T05:00:51ZAllogene Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-14T00:13:26Z
Allogene Therapeutics Q1 2026 Earnings Call Transcript
Benzinga âĸ 2026-05-13T22:12:51Z
William Blair Initiates Natera (NTRA) With Outperform
Insider Monkey âĸ 2026-05-02T14:35:44Z
Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common Stock
Insider Monkey âĸ 2026-05-01T09:23:15Z
Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In
Insider Monkey âĸ 2026-04-25T21:06:08Z
H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO)
Insider Monkey âĸ 2026-04-23T07:30:04Z
Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release â Has The Bull Case Changed?
Simply Wall St. âĸ 2026-04-15T21:04:09Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $22,000 | $95,000 | $156,000 |
| Operating Revenue | $0 | $22,000 | $95,000 | $156,000 |
| Expenses | ||||
| Interest Expense | $1,075,000 | $181,000 | $0 | - |
| Total Expenses | $206,933,000 | $257,504,000 | $314,587,000 | $335,692,000 |
| Other Income Expense | $-2,167,000 | $-19,637,000 | $-31,080,000 | $-9,444,000 |
| Other Non Operating Income Expenses | $215,000 | $-3,920,000 | $-17,835,000 | $-9,444,000 |
| Net Non Operating Interest Income Expense | $18,214,000 | $19,972,000 | $18,307,000 | $4,566,000 |
| Interest Expense Non Operating | $1,075,000 | $181,000 | $0 | - |
| Operating Expense | $206,933,000 | $257,504,000 | $314,587,000 | $335,692,000 |
| General And Administrative Expense | $56,781,000 | $65,205,000 | $71,673,000 | $79,305,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-190,886,000 | $-257,590,000 | $-327,265,000 | $-340,414,000 |
| Net Interest Income | $18,214,000 | $19,972,000 | $18,307,000 | $4,566,000 |
| Interest Income | $19,289,000 | $20,153,000 | $18,307,000 | $4,566,000 |
| Normalized Income | $-188,504,000 | $-245,173,570 | $-314,020,000 | $-340,414,000 |
| Net Income From Continuing And Discontinued Operation | $-190,886,000 | $-257,590,000 | $-327,265,000 | $-340,414,000 |
| Total Operating Income As Reported | $-209,315,000 | $-273,199,000 | $-327,737,000 | $-335,536,000 |
| Net Income Common Stockholders | $-190,886,000 | $-257,590,000 | $-327,265,000 | $-340,414,000 |
| Net Income | $-190,886,000 | $-257,590,000 | $-327,265,000 | $-340,414,000 |
| Net Income Including Noncontrolling Interests | $-190,886,000 | $-257,590,000 | $-327,265,000 | $-340,414,000 |
| Net Income Continuous Operations | $-190,886,000 | $-257,590,000 | $-327,265,000 | $-340,414,000 |
| Pretax Income | $-190,886,000 | $-257,147,000 | $-327,265,000 | $-340,414,000 |
| Special Income Charges | $-2,382,000 | $-15,717,000 | $-13,245,000 | - |
| Interest Income Non Operating | $19,289,000 | $20,153,000 | $18,307,000 | $4,566,000 |
| Operating Income | $-206,933,000 | $-257,482,000 | $-314,492,000 | $-335,536,000 |
| Per Share | ||||
| Diluted EPS | - | $-1.32 | $-2.09 | $-2.32 |
| Basic EPS | - | $-1.32 | $-2.09 | $-2.32 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-3,300,570 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-175,070,000 | $-227,610,000 | $-299,821,000 | $-321,241,000 |
| Total Unusual Items | $-2,382,000 | $-15,717,000 | $-13,245,000 | - |
| Total Unusual Items Excluding Goodwill | $-2,382,000 | $-15,717,000 | $-13,245,000 | - |
| Reconciled Depreciation | $12,359,000 | $13,639,000 | $14,199,000 | $14,295,000 |
| EBITDA (Bullshit earnings) | $-177,452,000 | $-243,327,000 | $-313,066,000 | $-321,241,000 |
| EBIT | $-189,811,000 | $-256,966,000 | $-327,265,000 | $-335,536,000 |
| Diluted NI Availto Com Stockholders | $-190,886,000 | $-257,590,000 | $-327,265,000 | $-340,414,000 |
| Tax Provision | $0 | $443,000 | $0 | - |
| Impairment Of Capital Assets | $2,382,000 | $15,717,000 | $13,245,000 | - |
| Research And Development | $150,152,000 | $192,299,000 | $242,914,000 | $256,387,000 |
| Selling General And Administration | $56,781,000 | $65,205,000 | $71,673,000 | $79,305,000 |
| Other Gand A | $56,781,000 | $65,205,000 | $71,673,000 | $79,305,000 |
| Diluted Average Shares | - | $194,811,756 | $156,931,778 | $143,147,165 |
| Basic Average Shares | - | $194,811,756 | $156,931,778 | $143,147,165 |
Fetched: 2026-05-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $292,542,000 | $422,179,000 | $512,233,000 | $666,882,000 |
| Total Assets | $415,905,000 | $548,710,000 | $642,837,000 | $821,579,000 |
| Total Non Current Assets | $158,156,000 | $245,324,000 | $183,722,000 | $292,755,000 |
| Other Non Current Assets | $37,386,000 | $33,390,000 | $16,896,000 | $19,856,000 |
| Investmentin Financial Assets | $8,043,000 | $80,673,000 | $0 | $59,151,000 |
| Current Assets | $257,749,000 | $303,386,000 | $459,115,000 | $528,824,000 |
| Other Current Assets | $7,539,000 | $10,910,000 | $10,418,000 | $11,504,000 |
| Cash Cash Equivalents And Short Term Investments | $250,210,000 | $292,476,000 | $448,697,000 | $517,320,000 |
| Cash And Cash Equivalents | $51,688,000 | $75,218,000 | $83,155,000 | $61,904,000 |
| Cash Equivalents | - | - | $78,536,000 | - |
| Cash Financial | - | - | $4,619,000 | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $83,253,000 | $90,756,000 | $95,121,000 | $101,124,000 |
| Long Term Debt And Capital Lease Obligation | $75,045,000 | $83,247,000 | $88,346,000 | $95,122,000 |
| Current Debt And Capital Lease Obligation | $8,208,000 | $7,509,000 | $6,775,000 | $6,002,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $123,363,000 | $126,531,000 | $130,604,000 | $154,697,000 |
| Total Non Current Liabilities Net Minority Interest | $90,849,000 | $91,008,000 | $93,525,000 | $100,969,000 |
| Other Non Current Liabilities | $15,804,000 | $7,761,000 | $5,179,000 | $5,847,000 |
| Current Liabilities | $32,514,000 | $35,523,000 | $37,079,000 | $53,728,000 |
| Payables And Accrued Expenses | $14,065,000 | $15,868,000 | $17,553,000 | $29,696,000 |
| Payables | $4,270,000 | $5,394,000 | $5,897,000 | $13,890,000 |
| Accounts Payable | $4,270,000 | $5,394,000 | $5,897,000 | $13,890,000 |
| Other Current Liabilities | - | - | $86,000 | - |
| Current Deferred Liabilities | - | - | $86,000 | $95,000 |
| Equity | ||||
| Common Stock Equity | $292,542,000 | $422,179,000 | $512,233,000 | $666,882,000 |
| Total Equity Gross Minority Interest | $292,542,000 | $422,179,000 | $512,233,000 | $666,882,000 |
| Stockholders Equity | $292,542,000 | $422,179,000 | $512,233,000 | $666,882,000 |
| Gains Losses Not Affecting Retained Earnings | $269,000 | $-89,000 | $-955,000 | $-9,926,000 |
| Other Equity Adjustments | $269,000 | $-89,000 | $-955,000 | $-9,926,000 |
| Retained Earnings | $-2,010,709,000 | $-1,819,823,000 | $-1,562,233,000 | $-1,234,968,000 |
| Long Term Equity Investment | - | $0 | $3,645,000 | $17,317,000 |
| Other | ||||
| Ordinary Shares Number | $229,413,523 | $212,210,597 | $168,642,238 | $144,438,304 |
| Share Issued | $229,413,523 | $212,210,597 | $168,642,238 | $144,438,304 |
| Tangible Book Value | $292,542,000 | $422,179,000 | $512,233,000 | $666,882,000 |
| Invested Capital | $292,542,000 | $422,179,000 | $512,233,000 | $666,882,000 |
| Working Capital | $225,235,000 | $267,863,000 | $422,036,000 | $475,096,000 |
| Capital Lease Obligations | $83,253,000 | $90,756,000 | $95,121,000 | $101,124,000 |
| Total Capitalization | $292,542,000 | $422,179,000 | $512,233,000 | $666,882,000 |
| Additional Paid In Capital | $2,302,753,000 | $2,241,879,000 | $2,075,252,000 | $1,911,632,000 |
| Capital Stock | $229,000 | $212,000 | $169,000 | $144,000 |
| Common Stock | $229,000 | $212,000 | $169,000 | $144,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $75,045,000 | $83,247,000 | $88,346,000 | $95,122,000 |
| Current Capital Lease Obligation | $8,208,000 | $7,509,000 | $6,775,000 | $6,002,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $10,241,000 | $12,146,000 | $12,665,000 | $17,935,000 |
| Current Accrued Expenses | $9,795,000 | $10,474,000 | $11,656,000 | $15,806,000 |
| Investments And Advances | $8,043,000 | $80,673,000 | $3,645,000 | $76,468,000 |
| Available For Sale Securities | $8,043,000 | $80,673,000 | - | $59,151,000 |
| Net PPE | $112,727,000 | $131,261,000 | $163,181,000 | $196,431,000 |
| Accumulated Depreciation | $-72,533,000 | $-62,538,000 | $-51,084,000 | $-36,885,000 |
| Gross PPE | $185,260,000 | $193,799,000 | $214,265,000 | $233,316,000 |
| Leases | $107,537,000 | $108,127,000 | $108,621,000 | $108,550,000 |
| Other Properties | $68,636,000 | $76,800,000 | $96,860,000 | $116,193,000 |
| Machinery Furniture Equipment | $9,087,000 | $8,872,000 | $8,784,000 | $8,545,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $198,522,000 | $217,258,000 | $365,542,000 | $455,416,000 |
| Current Deferred Revenue | - | - | $86,000 | $95,000 |
| Construction In Progress | - | - | $0 | $28,000 |
Fetched: 2026-05-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-149,632,000 | $-200,994,000 | $-239,249,000 | $-225,710,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-149,246,000 | $-200,300,000 | $-237,733,000 | $-220,519,000 |
| Cash Flow From Continuing Operating Activities | $-149,246,000 | $-200,300,000 | $-237,733,000 | $-220,519,000 |
| Operating Gains Losses | - | $1,688,000 | $10,672,000 | $12,883,000 |
| Investing Activities | ||||
| Capital Expenditure | $-386,000 | $-694,000 | $-1,516,000 | $-5,191,000 |
| Investing Cash Flow | $95,559,000 | $75,688,000 | $163,289,000 | $106,159,000 |
| Cash Flow From Continuing Investing Activities | $95,559,000 | $75,688,000 | $163,289,000 | $106,159,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $22,354,000 | $112,047,000 | $91,112,000 | $0 |
| Financing Cash Flow | $30,157,000 | $116,675,000 | $95,695,000 | $2,950,000 |
| Cash Flow From Continuing Financing Activities | $30,157,000 | $116,675,000 | $95,695,000 | $2,950,000 |
| Net Other Financing Charges | $6,908,000 | $2,280,000 | - | - |
| Net Common Stock Issuance | $22,354,000 | $112,047,000 | $91,112,000 | $0 |
| Common Stock Issuance | $22,354,000 | $112,047,000 | $91,112,000 | $0 |
| Other | ||||
| End Cash Position | $61,980,000 | $85,510,000 | $93,447,000 | $72,196,000 |
| Beginning Cash Position | $85,510,000 | $93,447,000 | $72,196,000 | $183,606,000 |
| Changes In Cash | $-23,530,000 | $-7,937,000 | $21,251,000 | $-111,410,000 |
| Proceeds From Stock Option Exercised | $895,000 | $2,348,000 | $4,583,000 | $2,950,000 |
| Net Investment Purchase And Sale | $95,945,000 | $76,382,000 | $164,805,000 | $111,350,000 |
| Sale Of Investment | $234,202,000 | $437,857,000 | $603,434,000 | $359,459,000 |
| Purchase Of Investment | $-138,257,000 | $-361,475,000 | $-438,629,000 | $-248,109,000 |
| Net PPE Purchase And Sale | $-386,000 | $-694,000 | $-1,516,000 | $-5,191,000 |
| Purchase Of PPE | $-386,000 | $-694,000 | $-1,516,000 | $-5,191,000 |
| Change In Working Capital | $-10,877,000 | $-24,799,000 | $-21,307,000 | $3,897,000 |
| Change In Other Working Capital | $-2,706,000 | $-20,773,000 | $-3,000 | $-21,000 |
| Change In Other Current Liabilities | $-6,368,000 | $-6,048,000 | $-6,613,000 | $-1,882,000 |
| Change In Other Current Assets | $-1,290,000 | $4,279,000 | $-1,455,000 | $-3,334,000 |
| Change In Payables And Accrued Expense | $-3,751,000 | $-1,765,000 | $-14,325,000 | $6,617,000 |
| Change In Accrued Expense | $-2,520,000 | $-1,262,000 | $-6,823,000 | $1,749,000 |
| Change In Payable | $-1,231,000 | $-503,000 | $-7,502,000 | $4,868,000 |
| Change In Account Payable | $-1,231,000 | $-503,000 | $-7,502,000 | $4,868,000 |
| Change In Prepaid Assets | $3,238,000 | $-492,000 | $1,086,000 | $2,517,000 |
| Other Non Cash Items | $4,355,000 | $5,250,000 | $6,581,000 | $2,329,000 |
| Stock Based Compensation | $37,642,000 | $51,743,000 | $65,951,000 | $83,600,000 |
| Asset Impairment Charge | $2,382,000 | $17,674,000 | $20,245,000 | - |
| Amortization Of Securities | $-4,221,000 | $-8,348,000 | $-6,809,000 | $2,891,000 |
| Deferred Tax | $0 | $443,000 | $0 | - |
| Deferred Income Tax | $0 | $443,000 | $0 | - |
| Depreciation Amortization Depletion | $12,359,000 | $13,639,000 | $14,199,000 | $14,295,000 |
| Depreciation And Amortization | $12,359,000 | $13,639,000 | $14,199,000 | $14,295,000 |
| Earnings Losses From Equity Investments | $0 | $1,688,000 | $10,672,000 | $12,883,000 |
| Net Income From Continuing Operations | $-190,886,000 | $-257,590,000 | $-327,265,000 | $-340,414,000 |
| Net Business Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Business | - | - | $0 | $0 |
| Amortization Cash Flow | - | - | - | $0 |
| Amortization Of Intangibles | - | - | - | $0 |
| Depreciation | - | - | - | $14,295,000 |
Fetched: 2026-05-24